metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	2	none	inconclusive results for: deaths (OS); deaths (OS) (extension); progression or deaths (PFS); objective responses (ORR); AE (any grade); AE (grade 3-4); AE leading to death (grade 5); SAE (any grade); STRAE (any grade); TRAE leading to death (grade 5); Anaemia TRAE (grade 3-4); Asthenia TRAE (grade 3-4); Constipation TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Febrile neutropenia TRAE (grade 3-4); Peripheral neuropathy TRAE (grade 3-4)	suggested 80 % decrease in DOR but the degree if certainty is unassessable suggested 56 % decrease in AE leading to treatment discontinuation (any grade) but the degree if certainty is unassessable suggested 62 % decrease in TRAE (any grade) but the degree if certainty is unassessable suggested 45 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable suggested 63 % decrease in TRAE leading to discontinuation (any grade) but the degree if certainty is unassessable suggested 80 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable	-
	pembrolizumab alone vs. Standard of Care (SoC)	1	none	inconclusive results for: progression or deaths (PFS); DOR	statistically conclusive 43 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 3.9-fold increase in objective responses (ORR) but the degree if certainty is unassessable suggested 3.6-fold increase in objective responses (ORR) (extension) but the degree if certainty is unassessable	-

mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive

versus Standard of Care (SoC)